Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer

Conclusion: Our real-world data suggests that first line use of ICI combined with chemotherapy demonstrates better cost-effectiveness and similar survival outcomes for mUC patients, when compared with subsequent ICI therapy after chemotherapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research